Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review.

IF 1.4 Q4 ONCOLOGY
Jie Tang, Xiu-Wen Li, Yong Wu, Zhen Su, Yan He, Xue-Wen Sun, Xiao-Long Cao, Yi-Hua Li, Bi-Cheng Wang, Guo-Rong Zou
{"title":"Treating radiation‑related nasopharyngeal necrosis with endostar in patient with nasopharyngeal carcinoma: A report of two cases and a literature review.","authors":"Jie Tang,&nbsp;Xiu-Wen Li,&nbsp;Yong Wu,&nbsp;Zhen Su,&nbsp;Yan He,&nbsp;Xue-Wen Sun,&nbsp;Xiao-Long Cao,&nbsp;Yi-Hua Li,&nbsp;Bi-Cheng Wang,&nbsp;Guo-Rong Zou","doi":"10.3892/mco.2023.2653","DOIUrl":null,"url":null,"abstract":"<p><p>Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.</p>","PeriodicalId":18737,"journal":{"name":"Molecular and clinical oncology","volume":"19 1","pages":"57"},"PeriodicalIF":1.4000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/b0/mco-19-01-02653.PMC10288433.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/mco.2023.2653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Radiation-related nasopharyngeal necrosis (RRNN) is a rare and often fatal complication in patients with nasopharyngeal carcinoma (NPC). Currently, no standard treatments are recommended for RRNN. The effects of traditional conservative treatments are suboptimal, and surgery for RRNN cannot be performed by inexperienced doctors. In the present study, the use of Endostar in two patients with RRNN was evaluated. Two patients with RRNN were treated at the Department of Oncology, Panyu Central Hospital (Guangzhou, China). Endostar was administrated (15 mg/day from day 1 to day 7, every three weeks) intravenously for four and seven cycles in a male and a female patient, respectively. The effects of Endostar were assessed using magnetic resonance imaging (MRI) and a nasopharyngoscope. The symptoms of RRNN in both patients were relieved after treatment with Endostar. MRI and nasopharyngoscope analysis revealed that necrosis of the nasopharynx was substantially decreased and nasopharyngeal ulcers were healed. Endostar has the potential to be a novel, effective therapy for the treatment of patients with RRNN. However, clinical trials are required to confirm the results of the present study.

Abstract Image

Abstract Image

Abstract Image

恩度治疗鼻咽癌放射相关性鼻咽癌坏死:附2例报告并文献复习。
辐射相关性鼻咽癌(NPC)是鼻咽癌(NPC)患者中一种罕见且经常致命的并发症。目前,对于RRNN没有推荐的标准治疗方法。传统的保守治疗效果不理想,并且RRNN的手术不能由经验不足的医生进行。在本研究中,对两例RRNN患者使用恩度进行了评估。2例RRNN患者在中国广州番禺中心医院肿瘤科接受治疗。恩度(15mg /天,从第1天到第7天,每3周一次)分别在男性和女性患者中静脉注射4个和7个周期。采用磁共振成像(MRI)和鼻咽镜评估恩度的效果。两例患者经恩度治疗后RRNN症状均得到缓解。MRI和鼻咽镜分析显示鼻咽坏死明显减少,鼻咽溃疡愈合。恩度有可能成为一种治疗RRNN患者的新型有效疗法。然而,需要临床试验来证实本研究的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
108
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信